Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma

Sathyan, Kizhakke Mattada; Sailasree, R.; Jayasurya, R; Lakshminarayanan, K.; Abraham, Thomas; Nalinakumari, K.R.; Abraham, Elizabeth; Kannan, S.

doi:10.1007/s00432-006-0111-y

Cited by 48 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The tongue and buccal mucosal carcinoma is reported to be biologically distinct. 33 Similarly, here we also found a difference in the distribution of H-Ras mutation between tongue and other oral sites, reaffirming our previous results. 33 This suggests an aetiological and biological difference in the carcinogenesis of the different intra-oral sites.…”

Section: Discussionsupporting

confidence: 92%

“…33 Similarly, here we also found a difference in the distribution of H-Ras mutation between tongue and other oral sites, reaffirming our previous results. 33 This suggests an aetiological and biological difference in the carcinogenesis of the different intra-oral sites. Even though Ras mutation is moderately high in Indian oral cancer scenario; none of the studies investigated its prognostic potential.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma

2007

View full text Add to dashboard Cite

Activating mutations of the Ras is a moderately frequent event in oral carcinogenesis in Indian patients. Ras pathway has essential roles in regulation of various phases of the cell cycle, especially at G 1 phase. Despite a large body of in vitro evidence, the multidimensional interaction between mutated Ras pathway and G 1 cell cycle regulatory proteins in tumours in vivo is poorly determined. In the present study, DNA samples were screened for mutations in hot spot exons of B-Raf and hot spot codons 12, 13 and 61 of H-, K-and N-Ras by PCR-SSCP. Mutations were confirmed by direct sequencing. Expression of G 1 cell cycle regulatory proteinscyclin D1, CDK4, Rb, p53, p16 and p21 and proliferation marker PCNA was analysed immunohistochemically. The results revealed the absence of B-Raf mutations in oral carcinoma in spite of 12.5% of the samples showing H-Ras mutation. The H-Ras mutant cases showed significantly low cyclin D1 (P ¼ 0.027) and CDK4 (P ¼ 0.046) expression and overexpression of Rb (P ¼ 0.011) and p16 (P ¼ 0.026). H-Ras mutant carriers also had significantly high recurrence-free survival (P ¼ 0.033). In summary the present study demonstrated an epistatic interaction between H-Ras mutation and G 1 cell cycle regulatory proteins in vivo. H-Ras mutation, thus, defines a molecular subtype of oral carcinoma with favourable outcome and unique biology.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma

2007

View full text Add to dashboard Cite

show abstract

“…Mutações no gene TP53 são alterações moleculares comuns nos CCE (17,31,47) ; no entanto, estudos têm demonstrado um padrão de mutação distinto associado a fatores etioló-gicos específicos (32,35) . Consequentemente, a localização do câncer de boca pode determinar diferentes padrões de mutação, como o encontrado nos CCE de lábio e intrabucal (32) .…”

Section: Resumo Unitermosunclassified

Análise comparativa da imunoexpressão da proteína p53 (clones DO-7 e PAb-240) em carcinomas de células escamosas intrabucais e labiais

Júnior¹,

Bernardo²,

Balassiano³

et al. 2009

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Introdução: A carcinogênese caracteriza-se como um processo multifatorial, e a inativação da proteína p53 é uma alteração genética comumente observada nos carcinomas de células escamosas de boca (CCEB). Objetivo: Analisar e comparar a imunoexpressão da proteína p53, por meio dos clones DO-7 e PAb-240, em CCEB com localização intrabucal e em lábio inferior. Material e métodos: Foram selecionados 40 casos de CCEB, sendo 20 de localização intrabucal e 20 em lábio inferior. Foi realizado um estudo imuno-histoquímico utilizando os anticorpos anti-p53 clone DO-7 e PAb-240. A imunoquantificação foi realizada por meio de análise digital de imagem, e os resultados, submetidos a tratamentos estatísticos. Resultados: A imunoexpressão da proteína p53 foi verificada com o anticorpo DO-7 em 13 casos (65%) de carcinoma intrabucal e em 19 (95%) de carcinoma de lábio inferior. Imunorreatividade para o anticorpo PAb-240 foi observada em 9 casos (45%) de lesões intrabucais e em 15 (75%) localizados em lábio inferior. Não foram observadas, segundo o teste de Mann-Whitney, diferenças estatisticamente significativas (p > 0,05) na expressão da proteína p53 entre as duas localizações estudadas, independentemente do anticorpo avaliado. Foram identificadas, pelo teste de Wilcoxon, diferenças estatisticamente significativas entre a expressão dos clones DO-7 e PAb-240 em cada um dos grupos analisados (valor p = 0,013 -lábio inferior; valor p = 0,016 -intrabucal). Conclusões: A expressão da proteína p53 observada nos CCEB, com localizações intrabucais e labiais, sugere a ocorrência de mutações no gene TP53. As diferenças quantitativas obtidas entre os anticorpos estudados, independentemente da localização das lesões, refletem uma especificidade distinta entre os clones DO-7 e PAb-240. O desenvolvimento de mais estudos será fundamental para estabelecer o anticorpo mais adequado para proteína p53 em CCEB. Background: Carcinogenesis is a multifactorial process and inactivation of p53 protein is a genetic change commonly observed in oral squamous cell carcinomas (OSCC). Objectives: To analyze and compare the expression of p53 protein through antibodies DO-7 and PAb-240 in OSCC samples located in the oral cavity and lower lip. Material and methods: Forty cases of OSCC were selected and divided into oral cavity and lower lip groups (20 cases each).Immunohistochemical technique was performed using antibodies

show abstract

“…Literature search revealed scarce studies on the comparative analysis of molecular expression in OSCCs at different sites. [6][7][8] It has been established that p16 and p21 expressions were significantly different in buccal and tongue carcinomas. In combined analysis, simultaneous downregulation of p16 and p21 was seen in 47% of tongue cancer cases as against 28% in buccal mucosa carcinomas.…”

Section: Introductionmentioning

confidence: 99%

“…In combined analysis, simultaneous downregulation of p16 and p21 was seen in 47% of tongue cancer cases as against 28% in buccal mucosa carcinomas. 6 Telomerase activity has been reported to be significantly diverse among the tumors in the nonkeratinizing mucosa (buccal mucosa, alveolus, and floor of mouth) and tongue. 8 In another study, expression of cyclin D1 displayed a significant variation with respect to site, with higher manifestation in tongue tumors as compared with buccal mucosal OSCC.…”

Section: Introductionmentioning

confidence: 99%

Site-specific Oral Cancers are different Biological Entities

Sarode

Patil

2017

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

show abstract

Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma

Abstract: Thus, tongue and buccal cancers represent different biological subentities, and such differences should be considered in oral cancer management.

Cited by 48 publications

References 25 publications

H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma

H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma

Análise comparativa da imunoexpressão da proteína p53 (clones DO-7 e PAb-240) em carcinomas de células escamosas intrabucais e labiais

Site-specific Oral Cancers are different Biological Entities

Contact Info

Product

Resources

About